JINYU(SH:600201)2015-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 20.57% to CNY 166,053,942.25 compared to the same period last year[8]. - Operating income slightly increased by 0.16% to CNY 336,724,038.26 compared to the previous year[8]. - Basic and diluted earnings per share increased by 20.41% to CNY 0.59 compared to the previous year[8]. - Total profit increased by 34.28 million RMB, a growth of 20.94%, attributed to reduced costs and expenses in the biopharmaceutical sector[16]. - Net profit rose by 28.36 million RMB, an increase of 20.58%, driven by lower costs and expenses in the biopharmaceutical sector[16]. - The total comprehensive income for the period was CNY 166,158,790.91, down from CNY 137,802,948.32, indicating a decrease of about 17.0%[32]. - Net profit for Q1 2015 was CNY 137,847,155.55, compared to CNY 166,661,709.19 in the previous period, reflecting a decline of approximately 17.3%[31]. Assets and Liabilities - Total assets increased by 5.62% to CNY 2,215,955,595.41 compared to the end of the previous year[8]. - Total current assets increased to CNY 1,479,474,907.81 from CNY 1,368,455,849.73, representing a growth of approximately 8.1%[22]. - Total non-current assets increased to CNY 736,480,687.60 from CNY 729,538,941.80, showing a growth of approximately 0.4%[23]. - Total liabilities decreased from CNY 467,500,864.84 to CNY 414,510,877.81, a reduction of about 11.3%[24]. - The total liabilities increased from CNY 383,877,072.58 to CNY 479,530,514.51, marking an increase of about 24.9%[29]. - Owner's equity increased to CNY 1,801,444,717.60 from CNY 1,630,493,926.69, representing a growth of approximately 10.5%[24]. Cash Flow - Cash flow from operating activities decreased significantly by 94.98% to CNY 6,619,947.07 compared to the same period last year[8]. - Cash received from operating activities decreased by 87.64 million RMB, a decline of 94.33%, mainly due to the previous year's transfer of subsidiary receivables[16]. - The net cash flow from operating activities for Q1 2015 was CNY 68,478,710.26, a significant improvement compared to a net cash outflow of CNY 27,494,020.22 in the same period last year[41]. - Total cash inflow from operating activities was CNY 114,931,340.40, up from CNY 96,427,956.15 year-over-year, indicating a growth of approximately 19.5%[42]. - The company’s cash flow management resulted in a net increase of CNY 40,925,044.26 in cash and cash equivalents during the quarter[43]. Shareholder Information - The total number of shareholders reached 11,650 at the end of the reporting period[11]. - The largest shareholder, Inner Mongolia Agricultural and Animal Husbandry Pharmaceutical Co., Ltd., holds 11.75% of the shares[11]. Operational Metrics - Accounts receivable increased by 128.16 million RMB, a rise of 74.59%, primarily due to sales in the biopharmaceutical sector not reaching the concentrated collection period[14]. - Prepayments increased by 30.15 million RMB, a significant increase of 332.92%, mainly for the purchase of fixed assets[14]. - The company’s operating costs decreased by 19.23 million RMB, a reduction of 16.76%, mainly due to lower costs in the biopharmaceutical sector[16]. - Inventory remained stable, with a slight increase from CNY 217,212,339.50 to CNY 218,453,296.15, reflecting a growth of 0.57%[22]. Strategic Decisions - The company decided to terminate the application for a non-public stock issuance aimed at raising 799 million RMB for working capital, due to sufficient internal funds[17]. - The company plans to grant 560,000 restricted stocks at a price of 26.34 RMB per share to three incentive targets[18].